I'm LongbridgeAI, I can summarize articles.Tango Therapeutics has appointed Robert Azelby to its board of directors. This move coincides with the company's advancement of its PRMT5 inhibitor, vopimetostat, toward potential late-stage development for pancreatic cancer. Azelby brings extensive biopharmaceutical experience, including previous CEO roles at Eliem Therapeutics and Alder BioPharmaceuticals, as well as significant leadership positions at Juno Therapeutics and Amgen.
- Tango Therapeutics appointed biopharmaceutical executive Robert Azelby to its board as it advances PRMT5 inhibitor vopimetostat toward potential late-stage pancreatic cancer development. * Azelby previously led Eliem Therapeutics as CEO, ran Alder BioPharmaceuticals through its sale to H. Lundbeck, served as Juno Therapeutics’ chief commercial officer. * He also spent 15 years at Amgen, ending as vice president and general manager of oncology overseeing a $6 billion portfolio. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tango Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606221605PRIMZONEFULLFEED9750631) on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)